Quantcast

See headlines for BIEL
View Print Version
More from GlobeNewswire

BioElectronics Announces the Launch of the ‘Try & Tell’ Program

By GlobeNewswire,  December 07, 2017, 08:30:00 AM EDT

BioElectronics Announces the Launch of the ‘Try & Tell' Program


FREDERICK, MD, Dec. 07, 2017 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC Pink:BIEL), the maker of advanced wearable consumer pain management medical device ActiPatch, announced today the launch of their "Try and Tell" program in the United States.

The ActiPatch® Musculoskeletal Pain Therapy is a wearable medical device that is FDA cleared for non-prescription use. There is clinical evidence that in the UK, where a similar opioid crisis is unfolding, ActiPatch users reported:

  • Reduced opioid pain medication use by 33%
  • Reduced other prescription pain medication use by 65%
  • Reduced pain level by 57%
  • Reduced side-effects from overall pain medication usage

The "Try and Tell" program drove ActiPatch sales abroad and expect to achieve the same results in the United States. This Wall Street Journal award winning program is meant to help consumers gain experience with the technology with the sampling of the 7-Day ActiPatch Trial device. Which in turn, converts consumers at the rate of 83% to the 30 Day ActiPatch device.

To launch the "Try and Tell" program, we are offering consumers a FREE ActiPatch 7-Day Trial at www.tryActiPatch.com with the promo code TRYANDTELL. Our hope is to expose consumers to an alternative to opioids and other analgesics that is user friendly, without side effects, and actually WORKS!

ActiPatch is also happy to announce retail distribution in the United States through ANDA, as a national distributor. "We are pleased to get ActiPatch national distribution through ANDA to retailers; it is a HUGE win for us here in the United States and will be a catalyst for growth," said Keith Nalepka, VP of Sales and Marketing at BioElectronics Corp.

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com .





Paul Knopick
940.262.3584
pknopick@eandecommunications.com

Source: BioElectronics Corporation

This article appears in: News Headlines

Referenced Stocks: BIEL


Latest News Video









Today's Market Activity

NASDAQ 6875.08
35.00  ▲  0.51%
DJIA 24386.03
56.87  ▲  0.23%
S&P 500 2659.99
8.49  ▲  0.32%
Data as of Dec 11, 2017